WO2018021683A1 - Antioxidative composition containing uldavioside a compound - Google Patents

Abstract

The present invention relates to an antioxidative composition containing, as an active ingredient, a Uldavioside A compound isolated from an extract of Salicis radicis cortex, and it has been confirmed that the Uldavioside A compound has an antioxidative activity. Through this, it is expected that the Uldavioside A compound of the present invention can be used for the development of an excellent antioxidative composition.

Description

Antioxidant Composition Containing Uldabioside A Compound

The present invention relates to an antioxidant composition containing Uldavioside A (Uldavioside A) compound isolated from the extract of the root of the roots as an active ingredient.

Although it enjoys abundant economic and cultural benefits with the development of modern industry, it is accompanied by the extension of life expectancy and awareness of the quality of life due to adult diseases and the aging society.

In vivo, significant amounts of reactive oxygen species (ROS) are produced during oxidation for energy production. Most of these free radicals are destroyed by in vivo elimination mechanisms, but when free radicals are generated momentarily and the balance with the antioxidant defense system is broken, it causes various diseases (Aruoma O.I., et al., 1998). In addition, the role of free radicals originating from oxygen as the cause of aging as a phenomenon related to oxidation in the living body has emerged, and interest in their removal is increasing (Fridorich I., 1978).

In vivo factors such as reactive oxygen production include cellular metabolism, oxidase, and bacterial action. Ex vivo factors include contaminated air, increased metabolic rate, smoking, carcinogens, certain antibiotics, ultraviolet light, heat, and instant food. Excessive intake, and the like.

Types of active oxygen are generally non-radical hydrogen peroxides as well as radicals such as lipid radicals, superoxide radicals and hydroxy radicals (OH). , H ₂ O ₂ ), lipid peroxide, hypochlorous acid, N-chloramine components. These free radicals combine with proteins and unsaturated fatty acids to produce lipid peroxides, cause damage to DNA, RNA, etc., damage to the biofilm and weaken the immune system, hypertension, arteriosclerosis, heart failure, rheumatoid arthritis, allergies, cancer And various diseases and aging (Chung HY, 1992; Yagi K., 1987; Lopaczyski W., et al., 2001; Yu BP, 1994; Cooke MS, et al., 1997). In addition, free radicals are a major cause of oxidative stress and deeply related to aging, which is a major cause of chronic inflammatory diseases as well as age-related degenerative diseases. In many animals, the proportion of free radicals correlates with individual lifespan, and the amount of free radicals is a determinant of the aging progression of individuals (Yu BP, 1994).

Homeostasis maintenance by intracellular antioxidant effect can restore the function of the cells, which can prevent or delay the progression of aging as well as improve chronic inflammation control and immunity to increase the quality of healthy life. During the aging process, antioxidants are known to enhance mitochondrial activity, which is defective, and to maintain homeostasis and ultimately increase cell viability (Lee YH, et al., 2015; Yang TK, et al., 2013). .

As a result, research on antioxidants that effectively control these free radicals has naturally increased (Huh Suh, 2005). However, synthetic antioxidants such as dibutyl hydroxy toluene (BHT), butylated hydroxy aniosle (BHA), tert-butylhydroquinone (TBHQ), and the like, have thermal stability and human toxicity. This problem has been severely restricted in use (Jun BS, et al., 2001). Therefore, the development of natural antioxidants with safer and better efficacy has been steadily tried until now. Natural antioxidants are mostly plant-derived antioxidants, such as Schizandra chinensis extract (Jang EJ, et al., 1996), Hemp extract (Han MJ, et al., 1999), and citrus flavonoids (Cha JH, et al., 2000). , Mulberry (Kim HJ, et al., 2000) is known to have high antioxidant capacity.

Root bark is the dried bark and root bark of the elm tree belonging to the family Elm ( Ulmaceae ) (Ji, et al., 1988). It is reported that Rhizome skin is sweet, non-toxic, used for swelling, arthritis, gastric ulcer, gastrointestinal diseases, and also has an excellent effect on expectoration, anti-cancer, wound healing and inflammation (Duke JA, 1985). Natural products present in the roots of the roots include β-sitosterol, phytosterol, phymasterol, stimasterol, tannin, starch, and polysaccharides. In addition, studies on chemical composition (Matsuzaki T., et al., 1985) and chemical composition of Friedelin, Epiprieladelol, and Taraxerol, which are analgesic compounds, (Duke JA) , 1985), but few attempts have been made to study the various biological activities of root bark.

Thus, the present inventors were able to complete the present invention by confirming that the Uldavioside A compound isolated from the root extract of the root of the extract had excellent antioxidant activity in the course of studying the antioxidant composition containing the extract of the root of the root of the root. .

As a prior art, Korean Patent No. 0893166 describes the proliferation and antioxidative effects of fibroblasts of elm extract, and Korean Patent Laid-Open No. 2008-0036694 contains a composition containing a mixed herbal extract including roots Although the antioxidant effect of has been described, there is no mention of Uldabioside A compound is different from the configuration of the present invention.

In addition, as a non-patent document, Son B.W., et al. Describe the ulviobioside A compound isolated from the elm tree, but the antioxidant activity of the ulviovioside A compound has not been described.

It is an object of the present invention to provide an antioxidant composition containing as an active ingredient Uldavioside A (Uldavioside A) compound isolated from the extract of the roots.

The present invention relates to an antioxidant composition containing an Uldavioside A compound of Formula 1 as an active ingredient.

[Formula 1]

The antioxidant composition may be a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient.

The pharmaceutical composition may be added in 0.001% to 50% by weight of the Uldavioside A compound based on the total weight of the composition.

The pharmaceutical composition may be used for the prevention or treatment of diseases caused by oxides produced by free radicals.

Diseases caused by the oxides produced by the free radicals are aging, chronic alcoholism, atherosclerosis, cancer, coronary heart disease, cataracts, diabetes, Down syndrome, hepatitis, ischemia or reperfusion injury, rheumatoid arthritis, arthritis And at least one disease selected from the group consisting of renal failure, various degenerative neurological diseases, stroke attacks, atopic dermatitis, bronchitis, epilepsy, chronic obstructive disease, diabetic angiopathy and myocardial infarction.

In addition, the antioxidant composition may be a cosmetic composition.

The cosmetic composition may be added in 0.001% to 50% by weight of the Uldavioside A compound based on the total weight of the composition.

The cosmetic composition may be for preventing skin aging.

In addition, the antioxidant composition may be a health functional food having an antioxidant effect.

The dietary supplement may be added in an amount of 0.001% to 50% by weight based on the total weight of the composition.

Hereinafter, the present invention will be described in detail.

The Uldavioside A compound of Formula 1 may be synthesized according to a conventional method, may be prepared as a pharmaceutically acceptable salt, or may be separated and purified from the root extract.

The roots of the roots are dried bark and root bark of the cork layer of the elm, which belongs to the Ulmaceae family.

Elm belonging to the elm family is the elm ( Ulmus parvifolia JACQ), Ulmus pumila (Ulmus pumila), elm (Ulmus davidiana var japonica NAK), elm (Ulmus davidiana PLANCH), Black Elm (Ulmus per davidiana var suberosa), ovary ( Ulmus laciniata ), elm ( Ulmus) macrocarpa HANCE), and Ulmus macrocarpa var macrophylla NAK, and the like, but are not limited thereto.

The roots of the extract may be extracted with water, C1 to C4 lower alcohol or a mixture thereof as a solvent. The C1 to C4 alcohol may be selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol and isobutanol. Preferably it is extracted with water.

The compound isolated from the extract of the roots can be purified using column chromatography. The chromatography may include silica gel column chromatography, HP-20 column chromatography, RP-18 column chromatography, and LH-20 column chromatography. LH-20 column chromatography, and high-performance liquid chromatography can be used.

Diseases caused by the oxides produced by the free radicals are aging, chronic alcoholism, atherosclerosis, cancer, coronary heart disease, cataracts, diabetes, Down syndrome, hepatitis, ischemia or reperfusion injury, rheumatoid arthritis, arthritis And at least one disease selected from the group consisting of renal failure, various degenerative neurological diseases, stroke attacks, atopic dermatitis, bronchitis, epilepsy, chronic obstructive disease, diabetic angiopathy and myocardial infarction.

The aging may be aging due to the oxides produced by free radicals. Preferably it may be aging promoted by oxides produced by free radicals.

The neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, polyneuropatchy, epilepsy, brain disease or stroke stroke, dementia, and the like.

The antioxidant composition provides a pharmaceutical composition comprising the Uldabioside A compound of Formula 1 and an excipient. The compound may be added in an amount of preferably 0.001% to 50% by weight, more preferably 0.001% to 40% by weight, and most preferably 0.001% to 30% by weight based on the total weight of the total composition.

The pharmaceutical composition may be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, suppositories, and sterile injectable solutions according to conventional methods. . Carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, water, and the like in the Uldabioside A compound of the present invention. Prepared with a mixture of cross or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween-61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The dosage of the pharmaceutical composition of the present invention will vary depending on the age, sex, weight of the subject to be treated, the specific disease or pathology to be treated, the severity of the disease or pathology, the route of administration and the judgment of the prescriber. Dosage determination based on these factors is within the level of skill in the art and generally dosages range from 0.01 mg / kg / day to approximately 2000 mg / kg / day. More preferred dosage is 1 mg / kg / day to 500 mg / kg / day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.

The pharmaceutical composition of the present invention can be administered to mammals such as mice, livestock, humans, etc. by various routes. All modes of administration can be expected, for example, by oral, rectal or intravenous, muscle, subcutaneous, skin, intrauterine dural or cerebrovascular injections. Since the compound of the present invention has almost no toxicity and side effects, it is a drug that can be used safely even when taken for long periods of time.

In addition, the antioxidant composition may be a cosmetic composition.

The cosmetic composition of the Uldabioside A compound of Formula 1 is preferably 0.001% to 50% by weight, more preferably 0.001% to 40% by weight, most preferably 0.001% by weight based on the total weight of the total composition To 30% by weight may be added.

The cosmetic composition may be in the form of an emulsion, suspension, microemulsion, microcapsules, microgranules or ionic (liposomes), nonionic vesicle dispersant obtained by dispersing an oil phase in a solution, gel, solid or pasty anhydrous product, aqueous phase, It may be provided in the form of a cream, skin, lotion, powder, ointment, spray or cone stick. It may also be prepared in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.

The cosmetic composition is a fatty material, an organic solvent, a dissolving agent, a thickening agent and a gelling agent, a softening agent, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic type in the Uldabioside A compound of the present invention. Or nonionic emulsifiers, fillers, metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other commonly used in cosmetics It may contain adjuvants conventionally used in the cosmetic field such as ingredients.

The cosmetic composition may be selected from lotion, gel, oil-soluble liquid, cream, ointment and essence.

The cosmetic composition may be for preventing skin aging.

In addition, the antioxidant composition may be a health functional food having an antioxidant effect.

The health functional food provides a health functional food having an antioxidant effect, including the Uldabioside A compound of Formula 1 and a food acceptable additive.

The Uldabioside A compound is preferably added in an amount of 0.001% to 50% by weight, more preferably 0.001% to 30% by weight, most preferably 0.001% to 10% by weight based on the total weight of the food. Can be.

The health functional food includes the form of tablets, capsules, pills or liquids, and the food to which the extract of the present invention may be added, for example, various foods, beverages, gums, teas, vitamin complexes, health Functional foods;

The present invention relates to an antioxidant composition containing Uldavioside A (Uldavioside A) compound isolated from the extract of the root of the root, as an active ingredient, it was confirmed that the Uldavioside A compound has excellent antioxidant activity.

Through this, it is expected that the Uldavioside A compound may be used for the development of a composition for preventing or treating various diseases caused by oxides produced by active oxygen, an anti-aging related cosmetic composition, and an antioxidant health functional food. .

1 is an illustration showing the ^{1 H- 1 H COSY (bold lines} ) and the ¹ H- ¹³ C HMBC correlation (arrow) for cry rainy A seed (Uldavioside A) a compound of the present invention.

Figure 2 shows the antioxidant activity in C2C12 (A) and NIH3T3 (B) cells of the Uldabioside A compound of the present invention.

Figure 3 shows the DPPH radical scavenging ability of the Uldabioside A compound of the present invention.

Figure 4 shows the total antioxidant capacity of the Uldabioside A compound of the present invention.

Figure 5 shows the cytotoxicity results in C2C12 (A) and NIH3T3 (B) cells of the Uldabioside A compound of the present invention.

Hereinafter, a preferred embodiment of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. Rather, the information provided herein is to be thorough and complete, and to fully convey the spirit of the present invention to those skilled in the art.

Example 1 Isolation of Uldavioside A Compound

Root of the elm ( Ulmus) Davidiana Planch) was used to purchase dried roots from farmhouses. After adding 1 l of purified water to 10 g of dried root skin, the extract of root bark was extracted three times with a semi-continuous cold vacuum extractor for 12 hours at 25 ° C., and impurities were removed using a filter paper to obtain a root bark extract. . Increasing polarity in the order of 30% methanol, 50% methanol, 70% methanol and 100% methanol, and performed Diaion HP-20 column chromatography under isocratic elution conditions. Fractions were obtained (Fr. E-1 to E-3). Of these, Fr. Sepadex LH-20 column chromatography was performed on E-1 according to 70% methanol isocratic elution conditions to separate Uldabioside A compound (9 mg).

<Example 2. Identification of Physicochemical Structure of Uldavioside A Compound>

Uldavioside A;

Light brown powder;

¹ H NMR and ¹³ C NMR data see Table 1 below;

ESI-MS [M + H] ⁺ m / z 423.1, C ₂₀ H ₂₂ O ₁₀ .

Position	Uldavioside A
	δ C (ppm) a	δ H (ppm) b
2	82.9	4.59 (1H, doublet, J = 6.8 Hz)
3	68.6	3.98 (1 H, m)
4	28.4	2.84 (1H, dd, J = 16.5, 5.5 Hz), 2.53 (1H, dd, J = 16.5, 8.3 Hz)
4a	103.2
5	158.2
6	97.2	6.12 (1H, doublet, J = 2.0 Hz)
7	157.6
8	96.8	6.06 (1H, doublet, J = 2.0 Hz)
8a	156.9
9	132.1
10	115.2	6.82 (1H, doublet, J = 2.0 Hz)
11	146.2
12	146.3
13	116.1	6.75 (1H, doublet of doublets, J = 8.2 Hz)
14	119.9	6.70 (1H, doublet of doublets, J = 8.2, 2.0 Hz)
One'	108.7	5.47 (1H, doublet, J = 3.4 Hz)
2'	78.2	4.13 (1H, doublet, J = 2.7 Hz)
3 '	80.3
4'	75.4	4.07 (1H, d, J = 9.6 Hz), 3.84 (1H, d, J = 9.6 Hz)
5 '	64.9	3.60 (2H, m)

^{a 13} C NMR (150 MHz in CD ₃ OD) spectroscopy data

^{b 1} H NMR (600 MHz in CD ₃ OD) spectroscopy data

Example 3 Culture of Animal Cells

Animal cells were cultured to confirm the activity of the Uldabioside A compound of the present invention. At this time, animal cells were C2C12, a myocyte line, NIH3T3 cells, a fibroblast line. Each cell was loaded with DMEM (Dulbecco's Modified Eagle's Medium) medium containing 10% fetal bovine serum (FBS), 100 U / ml penicillin and 100 µg / ml streptomycin. Cultured in a% CO ₂ incubator.

Example 4 Confirmation of Antioxidant Effect of Uldavioside A Compound

Example 4-1. Inhibition of Hydrogen Peroxide Production by Uldabioside A Compound

Hydrogen peroxide (H ₂ O ₂ ) detection kit was used to confirm the antioxidant effect of the treatment of the Uldabioside A compound of the present invention.

After incubating the C2C12 and NIH3T3 cells cultured in Example 3 to 5 x 10 ⁵ cells per well in a 24-well plate and incubating for 24 hours, the Uldavioside A compound was added to the cells to be 1 μM, 10 μM and 20 μM. After the pretreatment for 1 hour by treatment, the glucose oxidase was treated to 7mU / ㎖ to produce hydrogen peroxide and incubated for 24 hours. At this time, C2C12 or NIH3T3 cells treated with nothing were used as a control.

Hydrogen peroxide secreted in cell culture was measured using a H ₂ O ₂ detection kit (biovision, USA). Experimental method was carried out based on the experimental method provided in the kit, the results are shown in FIG.

As shown in FIG. 2, it was found that the amount of hydrogen peroxide decreased in both C2C12 (2A) and NIH3T3 (2B) cells, depending on the treatment concentration of Uldabioside A compound of the present invention.

Example 4-2. Identification of free radical scavenging ability of Uldabioside A compound

DPPH (α, α-diphenyl-β-picrylhydrazyl) radical scavenging ability was confirmed in order to confirm the antioxidant effect according to the treatment of the Uldabioside A compound of the present invention. DPPH radical scavenging ability utilizes the principle that the free radicals are discolored from purple to yellow by the reaction of antioxidants in the sample with the free radicals DPPH reagent.

 0.2 ml of the Uldabioside A compound of the present invention was mixed with 0.8 ml of 0.4 mM DPPH solution dissolved in ethanol and reacted in the dark for 10 minutes. At this time, the Uldabioside A compound was treated to a final concentration of 1, 10, 20 and 50uM, ascorbic acid (ascorbic acid) and butyl hydroxyanisol (butylated hydroxyanisol, BHA) as a control was treated at the same concentration. After the end of the reaction was measured for absorbance at 517nm, DPPH radical scavenging ability was calculated using the following equation, the results are shown in Figure 3 and Table 2.

[expression]

DPPH radical scavenging ability (%) = (1-sample group absorbance-blank absorbance) × 100

Configuration	Free radical scavenging (IC 50 , uM)
Uldavioside A	8.6 ± 0.4
Ascorbic acid	8.4 ± 0.8
BHA	19.9 ± 0.3

As shown in FIG. 3, the DPPH radical scavenging ability of the Uldavioside A compound of the present invention was found to be significantly higher than that of ascorbic acid used as a control at a low concentration of 1 uM, and was similar to ascorbic acid at a concentration of 10 uM or more. On the other hand, compared with butylhydroxyanisole (BHA), another control group, it was found that the DPPH radical scavenging ability of the Uldabioside A compound of the present invention was significantly higher at all concentrations.

In addition, as can be seen from Table 2, the IC ₅₀ value for the DPPH radical scavenging ability of the Uldabioside A compound of the present invention, similar to ascorbic acid used as a control, it is lower than butylhydroxyanisole (BHA) Confirmed.

Through this, it was found that the activity of the free radical scavenging activity of the compound of Uldabioside A of the present invention is very good at a level similar to ascorbic acid.

Example 4-3. Determination of Total Antioxidant Capacity of Uldabioside A Compound

Was measured by using a TAS (total antioxidant capacity) is (measured in that Cu ^{2 +} is converted to Cu ⁺ by the antioxidant activity) Biovision's total antioxidant capacity colorimetric kit according to the present invention weep rainy seed A compound, methods Was performed according to the experimental method provided by Biovision.

Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carbocylic acid), used as a standard curve, was diluted by concentration, and ascorbic acid and butylhydroxyaniline were used as the uldabioside A compound or the control group. Sol is the absorbance values were measured after prepared to be 10uM, the Cu ^{+ 2} in each sample into each 10㎕ after reacting for 90 minutes at room temperature 570㎚.

A standard curve was obtained by using absorbance values of concentrations of trolox, and the total antioxidant capacity of each sample was calculated using the obtained standard curve, and the results are shown in FIG. 4.

As shown in Figure 4, the total antioxidant capacity of the Uldabioside A compound of the present invention was significantly higher than the butyl hydroxyanisole used as a control, it was shown to be similar to ascorbic acid.

From these results, it can be seen that the Uldabioside A compound of the present invention has a remarkably excellent antioxidant activity.

Example 5 Confirmation of Cytotoxicity of Uldabioside A Compound

Cytotoxicity by the Uldabioside A compound of the present invention was confirmed using the MTT assay method.

1 × 10 ⁵ C2C12 and NIH3T3 cells cultured in Example 3 in a 48-well plate Cells were aliquoted and incubated for 24 hours, and then DMEM medium containing 0.5% FBS, 100 U / ml penicillin and 100 µg / ml streptomycin was added and cultured for 18 hours. After 18 hours of incubation, the Uldavioside A compound was treated with 1 μM and 10 μM and incubated for 24 hours. At this time, C2C12 and NIH3T3 cells that did not process anything were used as a control. After 24 hours, the cells were treated with MTT solution at a concentration of 100 µg / ml, reacted for 3 hours at 37 ° C, the culture medium was removed, and the formed forazan precipitate was dissolved in 200 µl of dimethyl sulfoxide (DMSO) and absorbance at 570 nm. Was measured and the result is shown in FIG.

As shown in Figure 5, the survival rate of C2C12 (5A) and NIH3T3 (5B) cells treated with Uldabioside A compound was increased compared to the control.

Through this, it was found that the Uldabioside A compound of the present invention does not exhibit cytotoxicity.

Preparation Example 1. Pharmaceutical Formulations

Formulation Example 1-1. Manufacture of tablets

200 g of the Uldabioside A compound of the present invention was mixed with 175.9 g of lactose, 180 g of potato starch, and 32 g of colloidal silicic acid. 10% gelatin solution was added to the mixture, which was then ground and passed through a 14 mesh sieve. It was dried and the mixture obtained by adding 160 g of potato starch, 50 g of active and 5 g of magnesium stearate was made into a tablet.

Formulation Example 1-2. Preparation of Injection

100 g of 1 g of uldabioside A compound of the present invention, 0.6 g of sodium chloride and 0.1 g of ascorbic acid were dissolved in distilled water. The solution was bottled and sterilized by heating at 20 ° C. for 30 minutes.

Preparation Example 2 Preparation of Cosmetic Composition

Formulation Example 2-1. Cream manufacturers

To 5 g of Uldabioside A compound of the present invention, 4 g of cytosterol, 3 g of polyglyceryl 2-oleate, 0.7 g of ceramide, 2 g of ceteareth-4, 3 g of cholesterol, 0.4 g of dicetyl phosphate, 5.0 g of concentrated glycerin, and 22 g of sunflower oil , 0.5 g of carboxyvinyl polymer, 0.5 g of triethanolamine, a preservative and flavor traces, and purified water were mixed to have a total weight of 100 g, and a nutritious cream was prepared according to a conventional cream preparation method.

Formulation Example 2-2. Lotion manufacturers

To 8 g of 95% ethanol, 0.05 g of polypyrrolidone, 0.1 g of oleyl alcohol, 0.2 g of polyoxyethylene monooleate, 0.2 g of fragrance, 0.1 g of paraoxybenzoic acid methyl ester, a small amount of antioxidant, and a small amount of pigment were mixed and dissolved. 0.05 g of Uldabioside A compound of the present invention and 5 g of glycerine were dissolved in 85.33 g of purified water, and then the mixed solution was added and stirred to prepare a lotion containing an extract of the mixed herbal medicine.

Formulation Example 2-3. Latex manufacturing

1.2 g of cetyl alcohol, 10 g of squalane, 2 g of petrolatum, 0.2 g of paraoxybenzoic acid ethyl ester, 1 g of glycerin monoesterarade, 1 g of polyoxyethylene (20 mole added) monooleate and 0.1 g of fragrance were dissolved by heating at 70 ° C. 0.5 g of the undabiside A compound of the present invention, 5 g of dipropylene glycol, 2 g of polyethylene glycol-1500, 0.2 g of triethanolamine, and 76.2 g of purified water were heated and dissolved at 75 ° C. Both were emulsified by mixing, followed by cooling to prepare an oil-in-water (Oil-in-Water, O / W) type emulsion.

Formulation Example 2-4. Essence

5 g of 95% ethyl alcohol, 1.2 g of polyoxyethylene sorbitan monooleate, 0.3 g of kitulose, 0.2 g of sodium hyaluronate, 0.2 g of vitamin E-acetate, 0.2 g of sodium licorice, 0.1 g of paraoxybenzoic acid ethyl ester, 1 g of the uldabioside A compound of the present invention and an appropriate amount of pigments were mixed to prepare a cosmetic solution.

Preparation Example 3 Food Preparation

Formulation Example 3-1. Preparation of Cooking Seasonings

Uldabioside A compound of the present invention was added to the cooking seasoning in 1% by weight to prepare a cooking seasoning for health promotion.

Formulation Example 3-2. Manufacture of Flour Food

Uldabioside A compound of the present invention was added to the flour in 0.1% by weight, and using this mixture to prepare bread, cakes, cookies, crackers and noodles to produce health foods.

Formulation Example 3-3. Preparation of soups and gravy

Uldabioside A compound of the present invention was added to the soup and broth in 0.1% by weight to prepare a soup and broth for health promotion.

Formulation Example 3-4. Manufacture of dairy products

Uldabioside A compound of the present invention was added to the milk at 0.1% by weight, and the milk was used to prepare various dairy products such as butter and ice cream.

Formulation Example 3-5. Preparation of Vegetable Juice

0.5 g of Uldabioside A compound of the present invention was added to 1,000 ml of tomato juice or carrot juice to prepare vegetable juice for health promotion.

Formulation Example 3-6. Preparation of Fruit Juice

0.1 g of the Uldabioside A compound of the present invention was added to 1,000 ml of apple juice or grape juice to prepare vegetable juice for health promotion.

Claims (10)

1. An antioxidant composition, characterized in that it contains an uldavioside A compound of Formula 1 as an active ingredient.

   [Formula 1]

   
2. The method of claim 1,

   The composition is an antioxidant composition, characterized in that the pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient.
3. The method of claim 2,

   The pharmaceutical composition is an antioxidant composition, characterized in that the Uldabioside A compound is added in 0.001% to 50% by weight based on the total weight of the composition.
4. The method according to claim 2 or 3,

   The pharmaceutical composition is an antioxidant composition, characterized in that it is used for the prevention or treatment of diseases caused by the oxides produced by free radicals.
5. The method of claim 4, wherein

   Diseases caused by the oxides produced by the free radicals are aging, chronic alcoholism, atherosclerosis, cancer, coronary heart disease, cataracts, diabetes, Down syndrome, hepatitis, ischemia or reperfusion injury, rheumatoid arthritis, arthritis Antioxidant composition, characterized in that at least one disease selected from the group consisting of renal failure, various neurodegenerative diseases, stroke attacks, atopic dermatitis, bronchitis, epilepsy, chronic obstructive diseases, diabetic angiopathy and myocardial infarction.
6. The method of claim 1,

   The composition is an antioxidant composition, characterized in that the cosmetic composition.
7. The method of claim 6,

   The cosmetic composition is an antioxidant composition, characterized in that the Uldabioside A compound is added in 0.001% to 50% by weight based on the total weight of the composition.
8. The method according to claim 6 or 7,

   The cosmetic composition is an antioxidant composition, characterized in that for preventing skin aging.
9. The method of claim 1,

   The composition is an antioxidant composition, characterized in that the health functional food having an antioxidant effect.
10. The method of claim 9,

    The dietary supplement is an antioxidant composition, characterized in that the Uldabioside A compound is added in 0.001% to 50% by weight based on the total weight of the composition.

Images